Viral Vector And Plasmid Dna Testing Services Market Size to Exceed USD 1,846.9 Mn by 2032

The Viral Vector And Plasmid Dna Testing Services Market, estimated at USD 370.4 Mn in 2025, is expected to exhibit a CAGR of 25.8% and reach USD 1,846.9 Mn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

The key market players are focusing on various growth strategies partnership and others for research and development activities, which in turn is expected to fuel the growth of global viral vector and plasmid DNA testing services market over the forecast period. For instance, in December 2025, ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc., a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.

Global viral vector and plasmid DNA testing services market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that first appeared in Wuhan (province of Hubei, China), in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

The COVID-19 affected the economy in three main ways:  by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.

The COVID-19 had a positive impact on the global viral vector and plasmid DNA testing services market, as Key players operating in the market are focusing on development of DNA vaccines for the treatment of COVID-19 pandemic. For instance, in May 2025, AGC Biologics, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, partnered with Takara Bio, the biomedical business unit of Takara Shuzo Co., Ltd., to develop vaccine for COVID-19. As a result of this partnership, AGC Biologics is manufacturing the plasmid DNA intermediate vaccine for treatment of COVID-19 with Takara Bio.

Global viral vector and plasmid DNA testing services market: Key Developments

On March 9, 2025, Charles River Laboratories International, Inc., a pharmaceutical company, announced the launch of its off the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing. It is available immediately in Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP)-grade.

In March 2025, WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, a pharmaceutical company, announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA). This technology is a novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Good Manufacturing Practice (GMP)-grade.

Browse 32 Market Data Tables and 36 Figures spread through 208 Pages and in-depth TOC on “Global viral vector and plasmid DNA testing services market, By Service Type (Safety, Genetic Characterization, Purity, Identity and Potency), By End User (Pharmaceutical and Biotechnology Industries and Research Organizations), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/viral-vector-and-plasmid-dna-testing-services-market-3637

Key Takeaways of the Global viral vector and plasmid DNA testing services market:

• Global viral vector and plasmid DNA testing services market is expected to exhibit a CAGR of 25.8% during the forecast period, owing to increasing platform launch by the key market players for biological testing which include viral vector and plasmid DNA testing. For instance, on January 12, 2025, Charles River Laboratories International, Inc., a pharmaceutical company, announced the launch of its eXpDNA plasmid platform, established from the Company’s contract development and manufacturing (CDMO) and biologics testing experience. The platform helps to significantly reduce the plasmid development and production timelines while streamlining the development journey for cell and gene therapy and vaccine developers with product quality and consistency.
• Among Service type, safety segment is expected to be the dominant region in the global viral vector and plasmid DNA testing services market, owing to increasing product or service launches by the manufacturers, which is expected to propel the market growth. For instance, in January 2025, Laboratory Corporation of America Holdings, a healthcare company, announced the launched a suite of cell and gene therapy development solutions from its drug development business of Covance. The solution is developed to accelerate the development of cell and gene therapy. Under this, Labcorp offers preclinical solutions and clinical solutions such as bioanalysis testing and services, and safety assessment.
• Among region, North America is expected to be the dominant region in the global viral vector and plasmid DNA testing services market, owing to adoption of various growth stratergie such as acquisition and others by the key market players. For instance, in March 2025, Wacker Biotech US Inc., a biotechnology company based in the U.S., announced the acquisition of Genopis Inc., a plasmid DNA manufacturer company based in San Diego, U.S. Under this acquisition Wacker Biotech US Inc. acquired a plasmid DNA (pDNA) CDMO (Contract Development and Manufacturing Organization) site and its associated business.
• Major players operating in the global viral vector and plasmid DNA testing services market include Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KgaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, Genezen Laboratories, Akron Biotech., Catalent, Inc, AcuraBio., CATUG Biotechnology., Creative Biogene and Aldevroz